Medicare spending on GLP-1 drugs reached $5.7 billion in 2022
- Medicare spending on GLP-1 drugs, including Ozempic, surpassed $5 billion in 2022 and is likely to continue growing as coverage expands, according to a KFF analysis. GLP-1 drugs Ozempic, Wegovy, and Mounjaro were initially developed to treat type 2 diabetes, and the Food and Drug Administration (FDA) has approved the use of Wegovy to reduce the...
More Articles
Massachusetts residents delay services due to high healthcare costs
High healthcare costs are burdening Massachusetts residents, with many delaying care due to prices, according to a survey from Beacon Research commissioned by Blue Cross Blue Shield of Massachusetts...Healthcare spending is higher in Medicare households, study finds
Healthcare spending is higher in households where Medicare covers all members, a KFF issue brief found. Around 66 million adults receive health insurance coverage through Medicare, including 59...2024 Medicare Advantage premiums remain low and stable
The average Medicare Advantage premium has remained low and stable, with many beneficiaries choosing plans with a zero-dollar monthly premium, according to data from eHealth, Inc. eHealth’s...MA Payment Reductions May Impact Value of Healthcare for Beneficiaries
The proposed 2025 Medicare Advantage Advance Notice would impact the value of healthcare for beneficiaries, resulting in higher costs, according to an analysis from the Berkeley Research Group...7 Out of 10 Americans Struggling With Medical Debt Owe Over $1,000
One in twelve adult Americans owe medical debt, largely those who are uninsured, low-income, or disabled, according to a report from the Peterson-KFF Health System Tracker. Research on rampant medical...What Utilization Management Strategies Do Payers Use to Lower Costs?
As healthcare spending rises in the United States, stakeholders are constantly working to address the drivers of high costs. The overutilization of healthcare services—including the provision of low- or no-value care—not only...2024 Employer Sponsored Health Plan Predictions: GLP-1s, Vendors, Data
Employers are stuck between a rock and a hard place in 2024, with unsustainable healthcare spending in their employer-sponsored health plans and a reticence to shift any more of the cost to their...2022 National Healthcare Spending Growth Slowed to Pre-COVID Levels
In 2022, national health expenditures hit $4.5 trillion, a 4.1 percent increase, with a couple of key spending areas seeing growth rates return to pre-pandemic levels, CMS announced in a fact...Sponsored Article
How Human and Artificial Intelligence Can Streamline Claims Reviews
Amid the shifting landscape of medical claims, the rise of high-cost and complex claims has become a significant challenge for payers. Recent data from the Peterson Center on Healthcare and Kaiser...Payers Embrace Healthcare IT for Cost Optimization, Member Engagement
Payers are investing in healthcare IT resources to support cost optimization and improve member experience, according to a study from EY-Parthenon and KLAS Research. As payers face operational and...Understanding Chronic Kidney Disease Coverage, VBC Opportunities
Efforts to improve chronic kidney disease coverage have evolved over the last several decades, but the disease remains costly and prevalent. Around 15 percent of the adult population in the US has chronic kidney disease (CKD), according...Sponsored Article